Classification of Platelet-Activating Anti-Platelet Factor 4 Disorders

Area of Science:

• Immunology
• Hematology
• Thrombosis Research

Background:

• Heparin-induced thrombocytopenia and thrombosis (HITT) involves IgG antibodies against platelet factor 4 (PF4), typically heparin-dependent.
• Vaccine-induced immune thrombocytopenia and thrombosis (VITT) emerged in 2021, triggered by adenoviral vector vaccines, broadening the scope of anti-PF4 disorders.
• Both HITT and VITT antibodies activate platelets via Fcγ receptor pathways.

Purpose of the Study:

• To classify the expanding range of platelet-activating anti-PF4 disorders.
• To differentiate between HITT-like and VITT-like conditions, including acute and chronic presentations.

Main Methods:

• A literature review was conducted from the perspective of a researcher-clinician identifying novel anti-PF4 disorders.
• Analysis focused on the clinical presentations, triggers, and immunological characteristics of various anti-PF4 conditions.

Main Results:

• Atypical HITT variants with heparin-independent activity and VITT-like disorders from natural adenovirus infection were identified.
• Chronic anti-PF4 disorders, such as VITT-like monoclonal gammopathy of thrombotic significance (VITT-like MGTS), represent a new, treatment-refractory entity.
• Both HITT and VITT antibodies recognize distinct PF4 epitopes, and management may necessitate treatments beyond anticoagulation, including IVIG or ibrutinib for VITT-like MGTS.

Conclusions:

• Clinicians and laboratorians must be aware of the evolving spectrum of acute and chronic anti-PF4 disorders.
• Understanding these distinctions is crucial for accurate diagnosis and effective patient management.
• The identification of novel anti-PF4 disorders necessitates updated diagnostic and therapeutic approaches.